X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: How justified is the premium valuation? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 31, 2004

    Pharma: How justified is the premium valuation?

    The BSE pharma index is one the key indicators of the performance of the stocks in the pharma sector and based on trailing twelve months earnings, the P/E of this index is about 21.5x. However, not all companies in the sector have valuation at these levels. While some are trading at premium there are others, which are at a discount to the index P/E. The pharma index itself is at a premium to market P/E of about 13. Let us try to analyse why the pharma index is valued at premium by the market and the further why some companies are valued at such a high premium while other are trailing on valuation front.
    Company P/E
    Abott 9.1
    Novartis 12.3
    Nicholas Piramal 14.7
    Aventis 14.8
    Wockhardt 18.0
    Cipla 22.2
    Glaxo 24.4
    Ranbaxy 24.5
    Dr Reddy 30.9
    Pfizer 42.1
    Sector 21.5
    Nifty 13.0

    In the table given beside we can see that while Abbott is amongst the lowest on valuation front. There are several reasons for the same. Firstly, the company has a very high share of traded goods (lack of manufacturing facilities in the country) in the topline, which gives an indication of the company's lack of involvement in the Indian markets. However, this type of business model can be highly effective once the new product patent regime is enforced in India. Post 2005, the company can aggressively launch new products in the Indian markets. The same is the case with Novartis, which again should be seen as a trading company. However, in case of Novartis we can see new products launches in the market in near future.

    The second valuation range is for Indian companies such as Nicholas Piramal and Wockhardt. While Nicholas is trading at about 15x, Wockhardt is trading at about 18x trailing twelve months price to earnings ratio. Wockhardt seems to have a higher valuation as its international business (Europe) has done pretty well in last three quarters. The company has presence in the generics business in the UK and recently, shifted its manufacturing operations from UK to India. This move will reduce the costs for the company improving margins further. However, sustainability of the growth that it has shown in the past is the key concern. In case of Nicholas Piramal, the company's strong presence in the domestic market can be advantageous for the company in the future when the patent regime will be enforced. It can use its to launch in-licensed products of international pharma majors, who do not have presence in the Indian market. However, company's contract manufacturing foray can give a boost to company's bottomline and topline and we may see an improvement in valuations of the company going forward.

    In the third range we have top Indian pharma companies, like Cipla, Ranbaxy and Dr Reddy's. All these companies are valued at about 2 times the Index valuation. These companies have been the face of the Indian pharmaceutical sector in the international arena. Although, the International market has been focus area for the Indian companies, Cipla's performance in the domestic market has been commendable. It is now the largest pharma company in the Indian market.

    Apart from the Indian market, Cipla has managed growth by its contract for bulk drug supply to leading generics companies such as Ivax and Watson. This is highly profitable for Cipla as it is one of the lowest cost producers of bulk drugs. While Cipla chose to focus on bulk drugs, Ranbaxy and Dr Reddy's has gone all alone in the tough generics market in the US and Europe. Offlate we saw some hiccups in the performance of Dr Reddy's, and the company is currently investing heavily in R&D and distribution network in the target markets in order to launch new products aggressively going forward. While Dr Reddy's is going through investment phase, Ranbaxy is reaping benefits from the investments it has made in the last few years. While growth for Ranbaxy has slowed down in US market, on back of higher base last year, the European market has come as a succor for it.

    The highest valuation among pharma companies is given to Glaxo and Pfizer. This can be attributed to their long presence in the Indian market, strong brands, market reach, and a very strong franchise amongst doctors. But the most important cause for their higher valuation is the fact that they are the largest pharma companies in the world with many proprietary products. With the patent regime coming into force from the year 2005, these companies are likely to benefit the most. However, this effect may not be visible in a year or two, in the longer run it seems, that they are likely to reap the benefits of a growing Indian pharma market.

    The growth of the pharma sector is generally better than the growth of the general economy, which. With, very low penetration levels of medicines in the country and changing life style we can be sure that in coming years the growth of the pharma sector may change its trajectory and go on a higher growth path. Apart from that, the cost competitiveness of the Indian producers can be a great advantage for them in the international market. Thus, it can be said that the premium valuation of the pharma industry is to some extent justified.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: How justified is the premium valuation?". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 16, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS